This research develops a targeted anti-VEGF therapy for wet age-related macular degeneration that can be injected under the skin rather than directly into the eye. In animal studies, the drug successfully reached the eye and reduced abnormal blood vessel growth, offering a safer, cheaper, and more convenient treatment for preventing blindness.

This research introduces the first simple mathematical model capable of capturing the cooperative folding of alpha helices, a fundamental protein structure. By revealing how these proteins fold, stabilize, and misfold, the model offers new insights into diseases such as Alzheimer's and Parkinson's while providing a fast, flexible platform for protein research.

This research investigates how Pseudomonas aeruginosa adapts to drinking water systems before causing human infections. By identifying a previously unknown gene essential for biofilm formation and survival, the work provides new insight into how dangerous bacteria prepare for infection and reveals potential targets for preventing disease before it develops.

This research investigates how aging changes blood stem cells, causing them to produce excess sticky platelets that increase the risk of heart attack and stroke. By identifying the genetic mechanisms behind this age-related shortcut, the work aims to develop therapies that reduce cardiovascular disease while improving healing in patients with low platelet counts.

This research investigates how lung mucus and its mucin molecules defend against Coccidioides, the fungus that causes Valley fever. By showing that mucins slow fungal growth, the work suggests mucus shapes infection before symptoms appear, opening new possibilities for earlier diagnosis and treatments against Valley fever and other infectious diseases.

This research uses agent-based mathematical modelling to study keloid scar growth. By simulating interactions among collagen, immune cells, and key scar-associated cell types, the model predicts how keloids expand without requiring harmful patient experiments. The approach may guide future treatments for keloids and broader skin-healing conditions.

This research develops orally administered nanoparticles that target the lymphatic system to treat lupus and osteoporosis simultaneously. By delivering drugs directly to affected tissues while avoiding the bloodstream, the approach reduces toxicity, suppresses inflammatory and bone-damaging genes, and offers a more effective strategy for treating these complex chronic diseases.

This research develops orally administered nanoparticle therapies for metronomic chemotherapy in ovarian cancer. By delivering smaller drug doses directly to tumours over extended periods, it aims to reduce side effects, overcome drug resistance, improve patient quality of life, and make long-term cancer treatment easier and more effective.

This research investigates whether the diabetes drug dapagliflozin (DAPA) can be repurposed to treat metabolic dysfunction-associated steatotic liver disease (MASLD). Using laboratory models, it examines fat accumulation and NHE1 ion channel function, aiming to develop a cost-effective treatment for two closely linked metabolic diseases with one existing medicine.

This research uses artificial intelligence to analyse immune-system data and predict vaccine effectiveness. By identifying early biological signals associated with strong, long-lasting immunity, the work aims to improve vaccine design, personalise vaccination strategies, and support development of universal vaccines capable of protecting against rapidly evolving infectious diseases.